ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $101.45 million. The enterprise value is $105.54 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.08 million shares outstanding. The number of shares has increased by 1.70% in one year.
| Current Share Class | 9.08M |
| Shares Outstanding | 9.08M |
| Shares Change (YoY) | +1.70% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 28.23% |
| Owned by Institutions (%) | 22.16% |
| Float | 6.02M |
Valuation Ratios
The trailing PE ratio is 56.82.
| PE Ratio | 56.82 |
| Forward PE | n/a |
| PS Ratio | 3.10 |
| Forward PS | n/a |
| PB Ratio | 3.12 |
| P/TBV Ratio | 3.15 |
| P/FCF Ratio | 19.08 |
| P/OCF Ratio | 13.16 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 13.80, with an EV/FCF ratio of 19.84.
| EV / Earnings | 57.02 |
| EV / Sales | 3.23 |
| EV / EBITDA | 13.80 |
| EV / EBIT | 19.13 |
| EV / FCF | 19.84 |
Financial Position
The company has a current ratio of 4.61, with a Debt / Equity ratio of 0.37.
| Current Ratio | 4.61 |
| Quick Ratio | 2.41 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.46 |
| Debt / FCF | 2.22 |
| Interest Coverage | 11.36 |
Financial Efficiency
Return on equity (ROE) is 6.01% and return on invested capital (ROIC) is 15.24%.
| Return on Equity (ROE) | 6.01% |
| Return on Assets (ROA) | 7.48% |
| Return on Invested Capital (ROIC) | 15.24% |
| Return on Capital Employed (ROCE) | 12.95% |
| Weighted Average Cost of Capital (WACC) | 7.27% |
| Revenue Per Employee | $454,923 |
| Profits Per Employee | $25,748 |
| Employee Count | 73 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 2.00 |
Taxes
In the past 12 months, ImmuCell has paid $44,543 in taxes.
| Income Tax | 44,543 |
| Effective Tax Rate | 2.31% |
Stock Price Statistics
The stock price has increased by +144.96% in the last 52 weeks. The beta is 0.62, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +144.96% |
| 50-Day Moving Average | 10.21 |
| 200-Day Moving Average | 9.16 |
| Relative Strength Index (RSI) | 62.21 |
| Average Volume (20 Days) | 13,941 |
Short Selling Information
The latest short interest is 14,706, so 0.16% of the outstanding shares have been sold short.
| Short Interest | 14,706 |
| Short Previous Month | 18,103 |
| Short % of Shares Out | 0.16% |
| Short % of Float | 0.24% |
| Short Ratio (days to cover) | 1.58 |
Income Statement
In the last 12 months, ImmuCell had revenue of $33.21 million and earned $1.88 million in profits. Earnings per share was $0.20.
| Revenue | 33.21M |
| Gross Profit | 13.56M |
| Operating Income | 5.60M |
| Pretax Income | 1.92M |
| Net Income | 1.88M |
| EBITDA | 7.77M |
| EBIT | 5.60M |
| Earnings Per Share (EPS) | $0.20 |
Full Income Statement Balance Sheet
The company has $7.91 million in cash and $12.01 million in debt, with a net cash position of -$4.10 million or -$0.45 per share.
| Cash & Cash Equivalents | 7.91M |
| Total Debt | 12.01M |
| Net Cash | -4.10M |
| Net Cash Per Share | -$0.45 |
| Equity (Book Value) | 32.77M |
| Book Value Per Share | 3.61 |
| Working Capital | 16.90M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $7.83 million and capital expenditures -$2.43 million, giving a free cash flow of $5.40 million.
| Operating Cash Flow | 7.83M |
| Capital Expenditures | -2.43M |
| Depreciation & Amortization | 2.16M |
| Net Borrowing | -1.60M |
| Free Cash Flow | 5.40M |
| FCF Per Share | $0.59 |
Full Cash Flow Statement Margins
Gross margin is 40.83%, with operating and profit margins of 16.87% and 5.66%.
| Gross Margin | 40.83% |
| Operating Margin | 16.87% |
| Pretax Margin | 5.79% |
| Profit Margin | 5.66% |
| EBITDA Margin | 23.39% |
| EBIT Margin | 16.87% |
| FCF Margin | 16.27% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.70% |
| Shareholder Yield | -1.70% |
| Earnings Yield | 1.76% |
| FCF Yield | 5.24% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |